The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.
I want you to remember Eli Lilly and Johnson & Johnson the next time you are about to dump a stock because of some bits of bad news.
The stocks of these two developmental concerns have slid recently, but there are reasons to believe they will improve.
Closed-end funds provide several benefits to investors over mutual funds.
South Korea is the plastic surgery capital of the world. These companies are manufacturing botox strains - but the big business is abroad, if they can crack the China and U.S. markets.
Few parts of this biotech space are more frustrating that what I have dubbed 'Tier 3' biotech concerns.
But is a Teva turnaround still coming after the stock's 70% loss in the past five years?
Healthcare giants Johnson & Johnson and Pfizer offer a tough choice for dividend investors seeking the best returns.
Biogen has to now be considered a more likely buyout target given the breadth of its product portfolio.
David Tepper's Appaloosa LP renews calls for changes at the top.